PFND Financials 07/16/2014 09:42:24 Pathfinder Ce

PFND Financials 07/16/2014 09:42:24
Pathfinder Cell Therapy, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 54 114 73 -
Cost of Revenue 37 50 26 -
Gross Profit 17 64 47 -
Operating Expenses
Research and Development 672 1,084 1,403 693
Sales, General and Admin. 944 1,040 2,262 134
Non-Recurring Items 161 - 8,127 -
Other - - - -
Operating Income (1,760) (2,060) (11,745) (827)
Income From Continuing Operations
Add'l Income/Expense Items 250 - 583 (459)
Earnings Before Interest and Tax (1,510) (2,060) (11,162) (1,286)
Interest Expense 195 96 108 8
Earnings Before Tax (1,705) (2,156) (11,270) (1,294)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,705) (2,156) (11,270) (1,294)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (1,705) (2,156) (11,270) (1,294)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (1,705) (2,156) (11,270) (1,294)